Edgewise (EWTX) CFO Michael Nofi Receives RSU/Option Awards

What Happened
Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, received two awards on August 12, 2026 totaling 73,125 derivative shares: 24,375 and 48,750 units. Both awards were reported at $0.00 per share (no cash paid) and are reported as derivative grants/awards rather than open-market purchases or sales.

Key Details

• Transaction date: August 12, 2026; Form 4 filed August 14, 2026 (appears filed within the normal 2-business-day window).
• Awards: 24,375 and 48,750 units (total 73,125); price reported $0.00 (award/grant code A, derivative).
• Shares owned after the transaction: not disclosed on the information provided in this summary.
• Footnotes from the filing:
  • F1: These are Restricted Stock Units (RSUs) that convert to one share each upon vesting; they vest in four equal annual installments beginning August 12, 2027.
  • F2: Another award (per filing) vests at 1/48th of the shares each month starting September 12, 2026, subject to continued service.
• No indication of a 10b5-1 plan, cashless exercise, gift, or tax-withholding sale disclosed in the provided details.

Context
These are grants/awards (not purchases or sales), meaning they represent future contingent rights to receive common stock if and when vesting conditions are met. Such awards are common compensation tools for executives and do not, by themselves, signal immediate buying or selling of company stock.